Our Pipeline

Our Pipeline

At Iktos, our unique approach leverages cutting-edge AI and robotics to advance drug discovery projects rapidly. Our innovative technologies, Generative AI, Synthesis planning and Iktos Robotics platform, enable us to deliver preclinical candidates in less than 2 years.

Explore our pipeline showcasing the breadth and depth of our ongoing projects.

Target / PathwayMTHFD2
Therapeutic AreasInflammation auto-immune diseases
Hit DiscoveryHit-to-LeadLead OptimizationPreclinical Candidate

Methylenetetrahydrofolate dehydrogenase 2

MTHFD2 is a mitochondrial enzyme involved in the folate-mediated one-carbon metabolism pathway. It plays a crucial role in controlling the fate and function of Th17 cells, and its inhibition promotes a Treg cell-like phenotype.

MTHFD2 deficiency has been shown to reduce disease severity in multiple in vivo inflammatory disease models. Pharmacological inhibition of MTHFD2 has the potential to treat various inflammatory conditions with an improved safety profile compared to JAK1 inhibitors.

We have applied our AI-driven drug discovery platforms, Makya and Spaya, to identify novel, potent, and selective MTHFD2 inhibitors. IKT525, a representative molecule from our lead series, is a potent (IC50 < 5nM), selective (>1000X over MTHFD1), and potential first-in-class MTHFD2 inhibitor with desirable drug-like properties. Preclinical candidate nomination is expected by 2025.

Target / PathwayConfidential Target
Therapeutic AreasOncology
Hit DiscoveryHit-to-LeadLead OptimizationPreclinical Candidate
Target / PathwayConfidential Target
Therapeutic AreasOncology
Hit DiscoveryHit-to-LeadLead OptimizationPreclinical Candidate
Target / PathwayConfidential Target
Therapeutic AreasImmuno oncology
Hit DiscoveryHit-to-LeadLead OptimizationPreclinical Candidate

Shared Program

How we work

How we work

Our drug discovery process integrates the power of AI and robotics at every step, iterating the DMTA cycle to converge on a Preclinical Drug Candidate in less than 2 years.

How we work

Our approach is distinguished by superior chemistry-based Generative AI that produces novel, synthesizable molecules optimized in a Structure-Based Drug Design context; and a unique way of bridging the gap between in silico and in vitro through AI-driven automated synthesis enabled by the integration of all our technological assets into a one-of-its-kind platform.

Technologies

Process

Makya

Generative AI for Drug Discovery

Makya

Makya, the first generative AI platform designed by chemists for chemists, streamlines drug discovery by creating diverse, novel, and medchem-like molecules that rapidly converge towards drug candidates.

Spaya

AI-Driven Retrosynthesis

Spaya

Spaya is our cutting-edge AI-driven retrosynthesis platform that transforms target compounds into commercially available starting materials in seconds. With Spaya, you can explore all plausible synthetic routes in real-time, making your research faster and more efficient.

Robotics

Robot Driven Chemistry

Robotics

Imagine a future where the full Design-Make-Test-Analysis cycle is totally automated.

Hit Discovery

Hit Discovery

Utilizing Generative AI, synthetic planning, and the Iktos Robotics platform, we efficiently design diverse and novel molecules. Our unique approach gives us access to immense chemical space, providing diverse, very novel, and high-quality compounds rapidly for highly challenging targets.

Hit-to-Lead and Lead Optimization

Hit-to-Lead and Lead Optimization

Fast optimization combining Iktos GenAI’s powerful structure-driven and Multi-Parametric Optimization capabilities with rapid DMTA iterations leveraging Iktos Robotics.

How we work

Partner with Iktos

Embark with us

Since our inception in 2016, we have consistently delivered value through over 60+ collaborations with leading pharmaceutical, biotech, and academic institutions. Our highly skilled team is dedicated to pushing the boundaries of AI-driven drug design, making us a trusted partner in your molecular odyssey.

get started today

Interested in learning more about our pipeline or collaborating with us?

Contact us to explore partnership opportunities and how we can accelerate your drug discovery efforts.

Interested in learning more about our pipeline or collaborating with us?